Axovant's seizure treatment spinoff has closed its series A round having received more than $133m in equity funding and $74.5m in project financing.

Eli Lilly, EMS, Takeda and ST Pharm are in line for exits after muscle disease therapy developer Avidity filed for a $100m initial public offering.

The oncology diagnostics technology provider has filed to go public in the US, with Legend Holdings and Eli Lilly set to exit through the flotation.

Babylon Health led a series B round for the healthcare measurement kiosk provider that also featured Rush University Medical Center for Health.

Appliance manufacturer Gree bought $89m of shares in an initial public offering in which the oncology therapy developer floated at the top of its range.

WuXi AppTec's Corporate Venture Fund and GV participated in a round that came two years after the drug discovery system developer raised money at a unicorn valuation.

Cancer diagnostics technology developer Inivata has secured $25m from NeoGenomics to take its total funding to more than $128m.

Roche has purchased Stratos Group's DNA sequencing spinoff five years after its corporate venturing subsidiary contributed to a $30m series B round.

Illumina and Amgen-backed genomic sequencing technology developer Oxford Nanopore has added $59.6m to a round that now totals $98.1m.

OCD drug developer Exscientia bagged $60m in a Novo-led round that also featured Bristol-Myers Squibb and existing corporate investor Evotec.